| Title | Anti-Cancer Drugs |
| Abbreviation | Anti-Cancer Drugs |
| Publication Type | Journal |
| Subject Area, Categories, Scope | Oncology (Q3); Pharmacology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4) |
| h-index | 105 |
| Overall Rank/Ranking | 10913 |
| SCImago Journal Rank (SJR) | 0.532 |
| Impact Score | 2.13 |
| Publisher | Lippincott Williams and Wilkins |
| Country | United States |
| ISSN | 09594973, 14735741 |
| Best Quartile | Q3 |
| Coverage History | 1990-2025 |
Anti-Cancer Drugs is a journal covering the technologies/fields/categories related to Oncology (Q3); Pharmacology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4). It is published by Lippincott Williams and Wilkins. The overall rank of Anti-Cancer Drugs is 10913. According to SCImago Journal Rank (SJR), this journal is ranked 0.532. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come. SJR acts as an alternative to the Journal Impact Factor (or an average number of citations received in last 2 years). This journal has an h-index of 105. The best quartile for this journal is Q3.
The ISSN of Anti-Cancer Drugs journal is 09594973, 14735741. An International Standard Serial Number (ISSN) is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic. Anti-Cancer Drugs is cited by a total of 1094 articles during the last 3 years (Preceding 2024).
The Impact IF 2024 of Anti-Cancer Drugs is 2.13, which is computed in 2025 as per its definition. Anti-Cancer Drugs IF is increased by a factor of 0.24 and approximate percentage change is 12.7% when compared to preceding year 2023, which shows a rising trend. The impact IF, also denoted as Journal impact score (JIS), of an academic journal is a measure of the yearly average number of citations to recent articles published in that journal. It is based on Scopus data.
Impact IF 2024 of Anti-Cancer Drugs is 2.13. If the same upward trend persists, Impact IF may rise in 2025 as well.
| Year | Impact IF |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.13 |
| 2023 | 1.89 |
| 2022 | 2.23 |
| 2021 | 2.26 |
| 2020 | 2.11 |
| 2019 | 2.38 |
| 2018 | 1.88 |
| 2017 | 1.77 |
| 2016 | 2.52 |
| 2015 | 2.41 |
| 2014 | 2.07 |
Anti-Cancer Drugs has an h-index of 105. It means 105 articles of this journal have more than 105 number of citations. The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times.
The ISSN of Anti-Cancer Drugs is 09594973, 14735741. ISSN stands for International Standard Serial Number.
An ISSN is a unique code of 8 digits. It is used for the recognition of journals, newspapers, periodicals, and magazines in all kind of forms, be it print-media or electronic.
The overall rank of Anti-Cancer Drugs is 10913. According to SCImago Journal Rank (SJR), this journal is ranked 0.532. SCImago Journal Rank is an indicator, which measures the scientific influence of journals. It considers the number of citations received by a journal and the importance of the journals from where these citations come.
| Year | SJR |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 0.532 |
| 2023 | 0.476 |
| 2022 | 0.471 |
| 2021 | 0.463 |
| 2020 | 0.651 |
| 2019 | 0.636 |
| 2018 | 0.684 |
| 2017 | 0.716 |
| 2016 | 0.780 |
| 2015 | 0.783 |
| 2014 | 0.744 |
| Year | Ranking |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 10913 |
| 2023 | 11285 |
| 2022 | 10871 |
| 2021 | 10705 |
| 2020 | 7704 |
| 2019 | 7745 |
| 2018 | 7028 |
| 2017 | 6600 |
| 2016 | 5990 |
| 2015 | 6068 |
| 2014 | 6210 |
Anti-Cancer Drugs is published by Lippincott Williams and Wilkins. It's publishing house is located in United States. Coverage history of this journal is as following: 1990-2025. The organization or individual who handles the printing and distribution of printed or digital publications is known as Publisher.
Visit the official website of the journal/conference to check the further details about the call for papers.
The IS0 4 standard abbreviation of Anti-Cancer Drugs is Anti-Cancer Drugs. This abbreviation ('Anti-Cancer Drugs') is well recommended and approved for the purpose of indexing, abstraction, referencing and citing goals. It meets all the essential criteria of ISO 4 standard.
ISO 4 (International Organization for Standardization 4) is an international standard that defines a uniform and consistent system for abbreviating serial publication titles and journals.
If your research field is/are related to Oncology (Q3); Pharmacology (Q3); Pharmacology (medical) (Q3); Cancer Research (Q4), then please visit the official website of this journal.
The acceptance rate/percentage of any academic journal/conference depends upon many parameters. Some of the critical parameters are listed below.
It is essential to understand that the acceptance rate/rejection rate of papers varies among journals. Some Journals considers all the manuscripts submissions as a basis of acceptance rate computation. On the other hand, few consider the only manuscripts sent for peer review or few even not bother about the accurate maintenance of total submissions. Hence, it can provide a rough estimation only.
The best way to find out the acceptance rate is to reach out to the associated editor or to check the official website of the Journal/Conference.
Anti-Cancer Drugs latest impact IF is 2.13. It's evaluated in the year 2024. The highest and the lowest impact IF or impact score of this journal are 2.52 (2016) and 1.77 (2017), respectively, in the last 11 years. Moreover, its average IS is 2.15 in the previous 11 years.
The Anti-Cancer Drugs has an SJR (SCImago Journal Rank) of 0.532, according to the latest data. It is computed in the year 2025. In the past 11 years, this journal has recorded a range of SJR, with the highest being 0.783 in 2015 and the lowest being 0.463 in 2021. Furthermore, the average SJR of the Anti-Cancer Drugs over the previous 11-year period stands at 2.15.
The latest h-index of the Anti-Cancer Drugs is 105.
The Anti-Cancer Drugs is published by the Lippincott Williams and Wilkins, with its country of publication being the United States.
The Anti-Cancer Drugs is currently ranked 10913 out of 27955 Journals, Conferences, and Book Series in the latest ranking. Over the course of the last 11 years, this journal has experienced varying rankings, reaching its highest position of 5990 in 2016 and its lowest position of 11285 in 2023.
The standard ISO4 abbreviation for the Anti-Cancer Drugs is Anti-Cancer Drugs.
Anti-Cancer Drugs is classified as a journal that the Lippincott Williams and Wilkins publishes.
The Anti-Cancer Drugs encompasses the following areas:
For a more comprehensive understanding of its scope, check the official website of this journal.
The Anti-Cancer Drugs is assigned the following International Standard Serial Numbers (ISSN): 09594973, 14735741.
The best quartile for the Anti-Cancer Drugs is Q3 (2024).
The Anti-Cancer Drugs coverage history can be summarized as follows: 1990-2025.
| Journal/Conference/Workshop/Book Title | Type | Ranking | Publisher | h-index | Impact Score |
|---|---|---|---|---|---|
| Journal of Academic Ethics | journal | 8704 | Springer Netherlands | 34 | 4.04 |
| Qualitative Research | journal | 1300 | SAGE Publications Ltd | 101 | 6.77 |
| Journal of Competition Law and Economics | journal | 11978 | Oxford University Press | 34 | 0.94 |
| Istanbul University - Journal of Electrical and Electronics Engineering | journal | 24654 | University of Istanbul | 0 | 0.00 |
| Canadian Journal of Education | journal | 15557 | Canadian Society for the Study of Education (CSSE) | 46 | 0.80 |
| Educational Measurement: Issues and Practice | journal | 6760 | Wiley-Blackwell Publishing Ltd | 68 | 1.54 |
| Korean Journal of Applied Microbiology and Biotechnology | journal | 22033 | Korean Society for Applied Microbiology | 0 | 0.00 |
| Natural Solutions | trade journal | 28581 | Innovision Health Media | 1 | 0.00 |
| Sapporo Medical Journal | journal | 29756 | Sapporo Medical University | 3 | 0.00 |
| Oral Radiology | journal | 9860 | Springer Japan | 28 | 2.17 |
| Year | Impact Score (IS) |
|---|---|
| 2025/2026 | Coming Soon |
| 2024 | 2.13 |
| 2023 | 1.89 |
| 2022 | 2.23 |
| 2021 | 2.26 |
| 2020 | 2.11 |
| 2019 | 2.38 |
| 2018 | 1.88 |
| 2017 | 1.77 |
| 2016 | 2.52 |
| 2015 | 2.41 |
| 2014 | 2.07 |
